Staphylococcus aureus Fatty Acid Auxotrophs Do Not Proliferate in Mice

Perturbation of Staphylococcus aureus Gene Expression by the Enoyl-Acyl Carrier Protein Reductase Inhibitor AFN-1252

(2013) Joshua B. Parsons et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

In vitroactivity (MICs and rate of kill) of AFN-1252, a novel FabI inhibitor, in the presence of serum and in combination with other antibiotics

(2013) Nachum Kaplan et al.   JOURNAL OF CHEMOTHERAPY

Pharmacokinetics, pharmacodynamics and efficacy of novel FabI inhibitor AFN-1252 against MSSA and MRSA in the murine thigh infection model

(2013) Mary A Banevicius et al.   JOURNAL OF CHEMOTHERAPY

Mode of Action,In VitroActivity, andIn VivoEfficacy of AFN-1252, a Selective Antistaphylococcal FabI Inhibitor

(2012) Nachum Kaplan et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Is bacterial fatty acid synthesis a valid target for antibacterial drug discovery?

(2011) Joshua B Parsons et al.   CURRENT OPINION IN MICROBIOLOGY

A novel two-gene requirement for the octanoyltransfer reaction of Bacillus subtilis lipoic acid biosynthesis

(2011) Natalia Martin et al.   MOLECULAR MICROBIOLOGY

Metabolic basis for the differential susceptibility of Gram-positive pathogens to fatty acid synthesis inhibitors

(2011) J. B. Parsons et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Rapid Visualization and Large-Scale Profiling of Bacterial Lipoproteins with Chemical Reporters

(2010) Kavita J. Rangan et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

Essentiality of FASII pathway for Staphylococcus aureus

(2010) Wendy Balemans et al.   NATURE

Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens

(2009) Sophie Brinster et al.   NATURE

Membrane lipid homeostasis in bacteria

(2008) Yong-Mei Zhang et al.   NATURE REVIEWS MICROBIOLOGY